Evidence map›Paper›PMID 21402697›Full record

ArticleThe Journal of biological chemistry2011

X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton.

Jinyi Liu, Dongyun Zhang, Wenjing Luo, Yonghui Yu, Jianxiu Yu, Jingxia Li, Xinhai Zhang, Baolin Zhang, Jingyuan Chen, Xue-Ru Wu and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. XIAP as a multifaceted molecule in Cellular Signaling.Apoptosis : an international journal on programmed cell death · 2022
    Review
  6. Article
  7. Article
  8. Electrostatic Forces Mediate the Specificity of RHO GTPase-GDI Interactions.International journal of molecular sciences · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. [Human RhoA is modified by SUMO2/3].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Jinyi LiuNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York 10987, USA.
Dongyun Zhang
Wenjing Luo
Yonghui Yu
Jianxiu Yu
Jingxia Li
Xinhai Zhang
Baolin Zhang
Jingyuan Chen
Xue-Ru Wu
Germán Rosas-Acosta
Chuanshu Huang
New York University · USAir Force Medical University · CNArmy Medical University · CNCenter for Drug Evaluation and Research · USThe University of Texas at El Paso · US

Funding

RESEARCH IN ENVIRONMENTAL HEALTH SCIENCES (CENTER GRANT)P30ES000260 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI COSTA, MAX · 1985 to 2020
$26.1M
Water/sediment &model &criteria for arsenic &chromeP42ES010344 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI COSTA, MAX · 2000 to 2010
$15.0M
Molecular Mechanisms of Nickel-Induced TumorigenicityR01CA112557 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUANG, CHUANSHU · 2004 to 2016
$2.9M
Mechanisms of Tumor Promotion Effects of B[a]PDER01ES012451 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUANG, CHUANSHU · 2004 to 2008
$1.7M
Molecular effects of SUMOylation on influenza virus infection: SUMO and NS1SC1AI098976 · NIAID · UNIVERSITY OF TEXAS EL PASO · PI ROSAS-ACOSTA, GERMAN · 2011 to 2014
$1.1M
NCI NIH HHS CA112557NCI NIH HHS R01 CA112557NIAID NIH HHS SC1 AI098976NIEHS NIH HHS ES000260NIEHS NIH HHS ES010344NIEHS NIH HHS ES012451NIEHS NIH HHS P30 ES000260NIEHS NIH HHS P42 ES010344NIEHS NIH HHS R01 ES012451
6 · The paper itself

Abstract

X-linked inhibitor of apoptosis protein (XIAP) overexpression has been found to be associated with malignant cancer progression and aggression in individuals with many types of cancers. However, the molecular basis of XIAP in the regulation of cancer cell biological behavior remains largely unknown. In this study, we found that a deficiency of XIAP expression in human cancer cells by either knock-out or knockdown leads to a marked reduction in β-actin polymerization and cytoskeleton formation. Consistently, cell migration and invasion were also decreased in XIAP-deficient cells compared with parental wild-type cells. Subsequent studies demonstrated that the regulation of cell motility by XIAP depends on its interaction with the Rho GDP dissociation inhibitor (RhoGDI) via the XIAP RING domain. Furthermore, XIAP was found to negatively regulate RhoGDI SUMOylation, which might affect its activity in controlling cell motility. Collectively, our studies provide novel insights into the molecular mechanisms by which XIAP regulates cancer invasion and offer a further theoretical basis for setting XIAP as a potential prognostic marker and specific target for treatment of cancers with metastatic properties.

Indexed as

Cell MovementActinsCell Line, TumorCytoskeletonGene Knockdown TechniquesGuanine Nucleotide Dissociation InhibitorsHumansNeoplasm InvasivenessNeoplasm MetastasisNeoplasm ProteinsNeoplasmsProtein Structure, Tertiaryrho Guanine Nucleotide Dissociation Inhibitor alpharho-Specific Guanine Nucleotide Dissociation InhibitorsSumoylationX-Linked Inhibitor of Apoptosis ProteinActinsARHGDIA protein, humanGuanine Nucleotide Dissociation InhibitorsNeoplasm Proteinsrho Guanine Nucleotide Dissociation Inhibitor alpharho-Specific Guanine Nucleotide Dissociation InhibitorsXIAP protein, humanX-Linked Inhibitor of Apoptosis Protein

Identifiers

PMID21402697
PMCPMC3091172
OpenAlexW2019005133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.